U.S., Oct. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07211932) titled 'Tofacitinib in Juvenile Idiopathic Arthritis' on Oct. 01.
Brief Summary: This study aims to evaluate, using real-world clinical practice data, the efficacy of tofacitinib in improving the clinical control of juvenile idiopathic arthritis (JIA) after 12 months of treatment.
Study Start Date: Dec., 2025
Study Type: OBSERVATIONAL
Condition:
Juvenile Idiopathic Arthritis (JIA)
Intervention:
DRUG: Tofacitinib
Patients received tofacitinib for the treatment of juvenile idiopathic arthritis (JIA).
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Consorci Sanitari de l'Alt Penedes i Garraf
Disclaimer: Curated by HT Syndication....